Literature DB >> 3145882

Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.

K Iinuma1, K Hayasaka, K Narisawa, K Tada, K Hori.   

Abstract

Serum amino acid pattern, blood ammonia, and serum valproic acid (VPA) levels were estimated in 75 epileptic children with and without VPA therapy. The incidence of patients with hyperammonaemia (greater than 60 mumol/l) in patients treated with only VPA or with a combination of VPA and other antiepileptic drugs was 19% and 20% respectively. Hyperammonaemia was not observed in patients receiving other drugs. Elevated levels of serum glycine, alanine and serine were more common in epileptic patients treated with VPA alone and with VPA in combination with other drugs than in patients receiving other drugs. A significant positive correlation was found between the serum levels of glycine and alanine, of glycine and serine, and of serine and alanine. These findings may indicate a mitochondrial dysfunction caused by VPA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145882     DOI: 10.1007/bf00441418

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

1.  Valproic acid and fatal hepatitis.

Authors:  J F Donat; J A Bocchini; E Gonzalez; R N Schwendimann
Journal:  Neurology       Date:  1979-02       Impact factor: 9.910

2.  Fatal hepatic failure and sodium valproate.

Authors:  G Le Bihan; J Bourreille; M Sampson; J Leroy; A M Szekely; A Coquerel
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

3.  Fatal liver failure in children on valproate.

Authors:  D Scheffner
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

4.  A case of fatal toxic hepatitis: recommendations for the administration of sodium valproate.

Authors:  H Gastaut; P Noel
Journal:  Epilepsia       Date:  1981-12       Impact factor: 5.864

5.  Valproic acid: a possible cause of proximal tubular renal syndrome.

Authors:  G R Lenoir; J L Perignon; M C Gubler; M Broyer
Journal:  J Pediatr       Date:  1981-03       Impact factor: 4.406

6.  A mechanism for valproate-induced hyperammonemia.

Authors:  F X Coude; D Rabier; L Cathelineau; G Grimber; P Parvy; P P Kamoun
Journal:  Pediatr Res       Date:  1981-06       Impact factor: 3.756

7.  Sodium valproate and acute hepatic failure.

Authors:  G M Addison; N S Gordon
Journal:  Dev Med Child Neurol       Date:  1980-04       Impact factor: 5.449

8.  Valproic acid hepatic fatalities: a retrospective review.

Authors:  F E Dreifuss; N Santilli; D H Langer; K P Sweeney; K A Moline; K B Menander
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

9.  Valproate-induced hepatic injury: analyses of 23 fatal cases.

Authors:  H J Zimmerman; K G Ishak
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

10.  Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients.

Authors:  J L Herranz; R Arteaga; J A Armijo
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

View more
  7 in total

1.  Valproic acid-associated encephalopathy.

Authors:  G L Jones; F Matsuo; J R Baringer; W H Reichert
Journal:  West J Med       Date:  1990-08

2.  Hyperaminoacidemia in epileptic children treated with valproic acid.

Authors:  M Castro-Gago; E Rodrigo-Saez; I Novo-Rodriguez; M F Camiña; S Rodriguez-Segade
Journal:  Childs Nerv Syst       Date:  1990-12       Impact factor: 1.475

3.  Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate.

Authors:  F Ebbesen; A Joergensen; E Hoseth; P H Kaad; M Moeller; V Holsteen; M Rix
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

4.  Valproic Acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitine.

Authors:  Martha G Blackford; Stephanie T Do; Thomas C Enlow; Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

5.  Paracetamol prevents hyperglycinemia in vervet monkeys treated with valproate.

Authors:  Jacques Viljoen; Jakobus J Bergh; Lodewyk J Mienie; Hercullas F Kotze; Gisella Terre'Blanche
Journal:  Metab Brain Dis       Date:  2012-02-17       Impact factor: 3.584

6.  NMR-based metabolomics in pediatric drug resistant epilepsy - preliminary results.

Authors:  Łukasz Boguszewicz; Ewa Jamroz; Mateusz Ciszek; Ewa Emich-Widera; Marek Kijonka; Tomasz Banasik; Agnieszka Skorupa; Maria Sokół
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

7.  Non-Hyperammonemic valproate encephalopathy.

Authors:  Omar Farooq; Pervaiz M Zunga; Mohd I Dar; Abdul Q Rather; Samia Rashid; Javid Basu; Ishrat H Dar; Mohd Ashraf
Journal:  Ann Neurosci       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.